中文 | EN | JP

Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration

2020年12月18日

Teijin Pharma Limited and TransThera jointly announced that they have entered into a strategic collaboration agreement for joint research and development of the innovative drugs in the target fields of oncology and inflammatory diseases.

-- 続きを読む (英語) --

TransThera Biosciences Has Filed the Second IND of TT-00420 to FDA for New Indication of Cholangiocarcinoma

2020年10月29日

Nanjing, China, October 29th, 2020--TransThera Biosciences announces today the Investigational New Drug (IND) application of TT-00420 for the indication of cholangiocarcinoma (CCA) has been submitted to Food and Drug Administration (FDA) in the United States.

-- 続きを読む (英語) --

TransThera Biosciences Lead Product TT-01025 Submitted Investigational New Drug (IND) Application to FDA

2020年8月18日

Seoul, South Korea and Nanjing, China – LG Chem Life Sciences (“LG Chem”), a division of LG Chem, and TransThera Biosciences jointly announce today the Investigational New Drug (IND) application of TT-01025 has been submitted to Food and Drug Administration (FDA) in the United States.

-- 続きを読む (英語) --

LG Chem Life Sciences and TransThera Biosciences Announce License Agreement for Potential Treatment of NASH and Other Chronic Inflammatory Conditions

2020年8月18日

NANJING, China, and SEOUL, Korea, August 18th, 2020 – LG Chem Life Sciences (“LG Chem”), a division of LG Chem, and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China, announced today that LG Chem has entered an exclusive license agreement with TransThera, for the development and commercialization of TransThera’s TT-01025, a highly selective oral small molecule inhibitor of Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) that has shown promising efficacy in pre-clinical investigation in non-alcoholic steatohepatitis (NASH). TT-01025 is expected to enter Phase I trial in early 2021 in the US.

-- 続きを読む (英語) --

TransThera Biosciences Initiates First Human Dose of TT-00920, a Novel PDE9 inhibitor for Chronic Heart Failure Treatment

2020年3月7日

NANJING, China, March 7, 2020 -- TransThera Biosciences Co. Ltd, a clinical-stage biotechnology company based in Nanjing, China, today announced that the first cohort of healthy volunteers has been dosed in Phase 1 clinical trial with TT-00920, a novel Phosphodiesterase 9 (PDE 9) inhibitor in development for the treatment of chronic heart failure.

-- 続きを読む (英語) --

TransThera Biosciences Announces IND Approval from FDA for Clinical Studies of TT-00920 to Treat Chronic Heart Failure

2019年12月17日

NANJING, China, Dec. 16, 2019 /PRNewswire/ -- TransThera Biosciences Co. Ltd, a clinical-stage biotechnology company based in Nanjing, China, announced today that the U.S. Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application for TT-00920, a novel small molecule inhibitor of Phosphodiesterase 9 (PDE 9) for the treatment of chronic heart failure.

-- 続きを読む (英語) --

TransThera Biosciences Lead Product TT-00420 Granted Orphan Drug Designation from FDA to Treat Cholangiocarcinoma

2019年11月7日

NANJING, China, Nov. 6, 2019 / -- TransThera Biosciences Co. Ltd, announced today that company received Orphan Drug Designation from US Food and Drug Administration (FDA) for TT-00420, a clinical stage investigational drug, for the treatment of cholangiocarcinoma.

-- 続きを読む (英語) --

TransThera Biosciences initiated Preclinical Development of TT-00920

2019年3月2日

NANJING, China, March 2nd, 2019 TransThera Biosciences Co. Ltd today announced that it has initiated preclinical development of its proprietary lead compound TT-00920. TT-00920 is a first-in-class, orally bioavailable drug candidate for the treatment of heart failure disease. “The advancement of TT-00920 into preclinical development is an important milestone for TransThera. Compelling preclinical results support that TT-00920 can improve cardiac function in both HFrEF (heart failure with reduced ejection fraction) and HFpEF (heart failure with preserved ejection fraction). We hope to bring a breakthrough therapy to patients suffering from this severe disease with our innovative drug. " said Dr. Frank Wu, founder and CEO of TransThera. The company expects to submit INDs in the US in the fourth quarter of 2019.

-- 続きを読む (英語) --

TransThera Biosciences Granted IND Approval from FDA to Soon Start Clinical Trials Targeting TNBC

2018年10月14日

TransThera Biosciences Co. Ltd, announced today that the company received FDA IND application approval for TT-00420, a novel small molecule investigational drug targeting Triple-Negative Breast Cancer (TNBC).

-- 続きを読む (英語) --